Skip to Content

Bupropion / Naltrexone Dosage

Applies to the following strength(s): 90 mg-8 mg

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Weight Loss

Initial dose:
-Week 1: One tablet (8 mg naltrexone/90 mg bupropion) orally once in the morning; then
-Week 2: One tablet orally twice a day (once in the morning and once in the evening); then
-Week 3: Two tablets orally in the morning and one tablet orally in the evening
Maintenance dose: Week 4 and onward: Two tablets orally twice a day (morning and evening)
Maximum dose: Two tablets orally twice a day

Comments:
-Discontinue therapy if a patient has not lost at least 5% of baseline body weight after 12 weeks at the maintenance dose.
-The effect of this drug on cardiovascular morbidity and mortality has not been established.
-The safety and effectiveness of this drug in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.

Use:
An adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of:
-30 kg/m2 or greater (obese) or
-27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)

Renal Dose Adjustments

-Mild renal impairment: Data not available
-Moderate to severe renal impairment: Maximum maintenance dose: One tablet orally twice a day (once in the morning and once in the evening)
-End-stage renal disease: Not recommended

Liver Dose Adjustments

-Maximum dose: One tablet orally once a day in the morning

Dose Adjustments

-Concomitant use of monoamine oxidase inhibitor (MAOI) antidepressant: Contraindicated. At least 14 days should elapse between discontinuation of an MAOI antidepressant and initiation of this drug, and conversely, at least 14 days should be allowed after stopping this drug before starting an MAOI antidepressant.
-Concomitant use of CYP450 2B6 inhibitors: Maximum dose of Contrave(R): One tablet orally twice a day (once in the morning and once in the evening)

Precautions

US BOXED WARNING:
-SUICIDAL THOUGHTS AND BEHAVIORS: This drug contains bupropion, which is the active ingredient in some antidepressant medications. Antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults in short-term trials. Monitor patients for worsening and emergence of suicidal thoughts and behaviors. This drug is not approved for use in pediatric patients or in the treatment of major depressive disorder or other psychiatric disorders.
-NEUROPSYCHIATRIC REACTIONS: Serious neuropsychiatric events have occurred in patients taking bupropion for smoking cessation. In many cases, a causal relationship to bupropion treatment is not certain. Although this drug is not approved for smoking cessation, observe patients for neuropsychiatric reactions.

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Not recommended

Other Comments

Administration advice:
-The tablets should not be cut, chewed, or crushed; swallow tablets whole.
-This drug should not be taken with a high-fat meal.
-Avoid drinking excessive amounts of alcohol while taking this drug. If you currently drink a lot of alcohol, do not suddenly stop; talk to your healthcare provider to determine the best way to gradually minimize your alcohol intake.

Monitoring:
-Measure blood pressure and pulse prior to starting therapy and at regular intervals, particularly among patients with controlled hypertension.
-Measure blood glucose levels prior to and during treatment in patients with type 2 diabetes.
-Monitor patients closely for clinical worsening, suicidality, and unusual changes in behavior, especially during the initial few months of a drug therapy course, or at times of dose changes.
-Observe patients for neuropsychiatric reactions and suicide risk.
-Advise families and caregivers of patients to monitor daily and report immediately the emergence of anxiety, agitation, irritability, unusual changes in behavior, and suicidality.
-Prior to treatment initiation, screen patients for a history of/risk factors for bipolar disorder.

Hide